Z Squared Inc. quarterly report, Q2 FY2023

Business context and reporting period

The supplied filing is Coeptis Therapeutics Holdings, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023, not a filing for Z Squared Inc. The company, formerly Bull Horn Holdings Corp., is a pharmaceutical development company focused on drug products and therapeutic technologies, including partnered cell-therapy programs. The merger that brought Coeptis into the public company was accounted for as a reverse merger.

Financial results and liquidity

MetricThree months ended June 30, 2023Six months ended June 30, 2023Comparable 2022 period
Revenue$0$0$0
Operating expenses$3.64 million$10.12 million$9.81 million and $25.58 million, respectively
Net loss$3.11 million$10.98 million$9.80 million and $28.98 million, respectively
Loss per share$0.14$0.52$0.75 and $2.26, respectively
Operating cash flowNot separately presented$(3.59) million$(2.00) million for six months
  • No sales or gross profit were reported, so gross margin is not meaningful. Management said it does not expect significant revenue for at least the next two years.
  • At June 30, cash was $3.24 million, total current assets $3.80 million, current liabilities $2.51 million, and total assets $7.16 million. Cash was $3.79 million at December 31, 2022.
  • Six-month financing cash inflows were $3.39 million, including approximately $3.0 million net proceeds from a June public offering. Investing cash use was $350,000 for a note receivable. Cash declined by $546,490 over the six months.
  • Current notes payable were $1.85 million and long-term notes payable $150,000. The balance sheet also included a $1.99 million warrant liability. Stockholders’ equity was $2.49 million, down from $4.80 million at year-end.

Material changes versus the prior comparable period

  • Operating expenses and net losses were lower than in 2022. Management attributed the reduction mainly to lower professional-services costs associated with equity transactions.
  • Research and development expense was $377,040 for the quarter and $402,780 for the half-year, compared with none in the 2022 periods. General and administrative expense was $3.22 million for the quarter and $9.64 million for the half-year.
  • Despite the lower net loss, operating cash use increased year over year. The cash-flow reconciliation includes significant noncash charges, including shares and warrants issued for services.
  • The six-month results included an $862,500 loss from changes in warrant fair value; second-quarter results included a $525,000 fair-value gain. These noncash valuation changes affected reported earnings.
  • Common shares outstanding increased from 19.57 million at December 31, 2022 to 24.40 million at June 30, 2023. The June offering issued common shares and warrants and also included pre-funded warrants, adding potential dilution.

Outlook, risks, contingencies, and unusual items

  • Going concern: The company reported an accumulated deficit of $76.72 million and stated that substantial doubt exists about its ability to continue as a going concern. Management expects to seek additional equity or debt financing; there is no assurance it will obtain funding or achieve profitability.
  • Debt defaults: The $1.5 million Purple BioTech note was in default at June 30. An amendment signed July 14 revised repayment into four milestone payments; the first was paid July 17. Separate secured notes of $200,000 and $150,000 were also in default at quarter-end. The company said it had verbal agreements with those lenders to convert principal to equity.
  • Development and transaction uncertainty: The company described an exclusive negotiation right concerning Deverra assets, subject to due diligence, definitive agreements, approvals, financing and other conditions. The proposed consideration included 4 million shares and $350,000 cash. The filing gives no assurance the transaction would close. A $350,000 advance to Deverra was recorded as a note receivable at June 30; subsequent advances brought total advances to $461,905, with the note due September 30, 2023.
  • Business priorities: The company is pursuing CD38-GEAR-NK and CD38-Diagnostic with VyGen and licensed CAR-T technology with the University of Pittsburgh. Management said it had shifted priority resources away from CPT60621. Development, commercialization and partnership timing remain uncertain.
  • Controls: Management concluded disclosure controls were not effective at June 30 because of material weaknesses, including inadequate segregation of duties. A new CFO was appointed in May 2023; management said remediation was ongoing.
  • The filing reported no material litigation. It identifies COVID-19-related uncertainty among business risks and refers investors to the risk factors in the company’s 2022 Form 10-K.

Important facts for investors to verify

  • Confirm the issuer identity: the supplied metadata says Z Squared Inc., while the filing itself names Coeptis Therapeutics Holdings, Inc.
  • Check the status and repayment performance of the defaulted Purple and other secured notes, and whether the proposed debt-to-equity conversions were completed.
  • Verify subsequent Deverra advances, repayment or application of the note receivable, and whether any definitive Deverra transaction closed.
  • Assess cash runway and financing needs against the going-concern disclosure and the company’s operating cash burn.
  • Review potential dilution from the June offering, outstanding warrants and equity awards, and track progress remediating the disclosed control weaknesses.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.